 Following several years of steady growth, Abbott Laboratories ABT , Financial reported disappointing results for the third quarter of 2022, causing investors to worry that further declines could be in store for the stock. Medical device sales were down sharply, adding to already-negative investor sentiment from an infant formula recall and production halt earlier this year due to an FDA inspection that found Cronobacter sakazakii bacteria, which can be deadly to infants, in several areas of the companys Sturgis, Michigan facility. 